Genor BioPharma Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Shanghai China (2007)
Status: No NME R&D (2007)

Organization Overview

First Clinical Trial
2011
NCT04175171
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Genor Biopharma Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Bone Neoplasms (Phase 1)

Brain Neoplasms (Phase 1)

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Colorectal Neoplasms (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Neoplasms (Phase 1)

Sarcoma (Phase 2)

Sarcoma, Alveolar Soft Part (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 23
  • # of Trial APIs: 13